 Successful foscarnet therapy cytomegalovirus retinitis AIDS patient hemodialysis rationale empiric dosing plasma level monitoring Foscarnet investigational antiviral agent treatment cytomegalovirus CMV retinitis AIDS patients available AIDS patients renal insufficiency major side effect nephrotoxicity report efficacy safety requirements foscarnet hemodialysis-dependent patient CMV retinitis Foscarnet weeks initial dosage mg/kg dialysis session Plasma concentrations monitored weekly dosage peak plasma levels range microM laboratory abnormalities preexisting anemia serum calcium phosphorus ionized calcium therapy Foscarnet useful alternative treatment CMV retinitis hemodialysis-dependent AIDS patients